Effect of Corona Virus on Intravitreal Injections

Not Applicable

• Conditions: Diabetic Macular Edema; Diabetic Retinopathy; Myopic Choroidal Neovascularisation; Age-Related Macular Degeneration; Choroidal Neovascularization
• Interventions: Drug: Anti-vascular endothelial growth factors (Anti-VEGFs)

• Registration Number: NCT05494775
• Lead Sponsor: Benha University

Brief Summary

During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.

Detailed Description

The corona virus pandemic may affects patients regular visits to ophthalmic clinic, we aim to study the sequel of the pandemic on intravitreal injections results in diabetic macular edema, wet age related macular degenerations, myopic choroidal new vascularization, and proliferative diabetic retinopathy.

Study Timeline

• Study Start: 2019-02-01
• Status Verified: 2022-08
• Study First Submitted: 2022-08-08
• Study First Submitted QC: 2022-08-08
• Last Update Submitted: 2022-08-08
• Study First Posted: 2022-08-10
• Last Update Posted: 2022-08-10
• Primary Completion: 2023-06-11
• Study Completion: 2023-07-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• patients with the following conditions (diabetic macular edema, wet age related macular degeneration, myopic choroidal new vascularization and retinal vein occlusion complicated with macular edema).

Exclusion Criteria

• patients that are known to have hypersensitivity to Anti-VEGFs.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Wet age related macular edema	Anti-vascular endothelial growth factors (Anti-VEGFs)	Cases with wet age related macular degenerations that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
Retinal vein occlusion	Anti-vascular endothelial growth factors (Anti-VEGFs)	Cases with macular edema secondary to retinal vein occlusion that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
Myopic choroidal new vascularization	Anti-vascular endothelial growth factors (Anti-VEGFs)	Cases with myopic choroidal new vascularization that are prepared for intravitreal injection of anti-vascular endothelial growth factors.
Diabetic macular edema	Anti-vascular endothelial growth factors (Anti-VEGFs)	Cases with diabetic macular edema that are prepared for intravitreal injection of anti-vascular endothelial growth factors.

Primary Outcome Measures

Name	Time	Method
Visual acuity	Baseline and monthly after injection till one year of follow-up	Assessing the changes in best corrected visual acuity in logMAR unit measured by snellen chart.

Secondary Outcome Measures

Name	Time	Method
Central subfield thickness	Baseline and monthly after injection till one year of follow-up	Assessing the changes in central macular thickness in microns measured by optical coherence tomography

Trial Locations

Locations (1)

Ahmed Abdelshafy Tabl; 🇪🇬 Banhā, Benha, Egypt